The global biopharmaceuticals contract manufacturing market size was evaluated at USD 40.12 billion in 2024 and is expected to grow around USD 115.99 billion by 2034, registering a CAGR of 11.2% from 2025 to 2034.
| Industry Worth | Details |
| Market Size in 2025 | USD 44.61 Billion |
| Market Size by 2034 | USD 115.99 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 11.2% |
Biopharmaceutical contract manufacturing refers to production outsourcing to a contract manufacturing organization (CMO). Outsourcing production helps businesses to scale up production without the need for investing heavily in manufacturing units and machinery, thus reducing costs and streamlining business operations so they can focus on their research and development.
The biopharmaceutical contract manufacturing market is rising in demand due to the shift of businesses from in-house manufacturing to outsourcing production manufacturing. The rapid increase in the number and research & development in biopharmaceuticals drives the market growth.
"We are thrilled to break ground on our long-planned site in Singapore. The progress we’ve made with many of our local partners is remarkable,
"As we continue to enhance our capabilities and capacities to deliver high-quality solutions that meet the evolving needs of our customers, the new Singapore site will help us better serve our customers both locally and around the world."
“Collaboration between Samsung Biologics and LegoChem Biosciences will enable us to deliver on our common goal to develop and manufacture efficient and safe therapeutics for patients,”
“We look forward to working with LegoChem Biosciences to support their pipeline of innovative ADC candidates and secure new opportunities in the fast-growing ADC field.”
North America
North America dominated the biopharmaceuticals contract manufacturing market in 2024. The presence of leading global players in the market gives the region a competitive edge over others. Furthermore, developments in the biopharmaceutical market and advancements in biotechnology fuel the growth of biopharmaceutical contract manufacturing. Companies are primarily focused on R&D and outsource production to a third party to streamline their business operations. Government-aided initiatives, along with favorable regulatory frameworks for biologics, are the market drivers for the market.
APAC
Asia-Pacific region is predicted to be the fastest-growing region in the biopharmaceutical contract manufacturing market in the forecasted period. The growth in biomanufacturing in the region is expected to boost the biopharmaceutical market as well. Many other market drivers, such as government initiatives and private investments in biomanufacturing and bioscience, contribute to the growth of the biopharmaceutical contract manufacturing market.
Europe
Europe is expected to be a rapidly growing region in the forecasted period of 2025-2034. It is already the second largest market share holder with the presence of many leading companies in the region. The rising demand for complex biologics and cell and gene therapies contributes to the market drivers. Furthermore, government support through investments and initiatives also plays a vital role in market growth.
Biopharmaceutical contract manufacturing is a competitive market with leading players all across the globe. With the advancements in technology and investment in research and development, the biopharmaceuticals market is booming, and so is the biopharmaceutical contract manufacturing market. Thermo Fisher Scientific, Pfizer Inc., Boehringer Ingelheim GmbH, Lonza, Inno Biologics Sdn Bhd, and Rentschler Biotechnologie GmbH are some of the global leading players with the largest market share.
The market is dominated by several companies, but the companies that are renowned for their remarkable contribution in the market are listed below:
Thermo Fisher Scientific was established by a merger between Thermo Electron and Fisher Scientific. It provides many kinds of products and services throughout 600+ locations across America, APAC, and EMEA regions. The company is one of the most prominent players in the biopharmaceutical contract manufacturing market and has substantially grown after its acquisition with Patheon.
Phizer Inc. plays a vital role in the biopharmaceuticals contract manufacturing market through one of its divisions, Pfizer Centreone, which is a global contract drug manufacturing organization (CDMO). The company recorded a revenue of US$ 63,627 million in the year 2024 and is growing at a rapid rate.
Boehringer Ingelheim GmbH is a leading global provider in biopharmaceutical contract manufacturing with expertise in the field of both mammalian and non-mammalian technologies. The net sales recorded by the company in 2024 were EUR 26,796 million.
Published by Ajit Bansod
